Introduction
============

The geographic and ethnic incidence of nasopharyngeal carcinoma (NPC) significantly differs worldwide. For example, NPC is commonly diagnosed in southern China and southeast Asia, yet it is rarely diagnosed in western Europe and North America.[@b1-cmar-10-3169],[@b2-cmar-10-3169] Radiotherapy, especially intensity-modulated radiotherapy (IMRT), is currently recognized as the primary treatment for NPC due to the complex anatomic site of NPC and its high radiosensitivity.[@b3-cmar-10-3169]

The American Joint Committee on Cancer (AJCC) staging system (seventh edition) has been widely applied to NPC patients. However, in contrast with the staging of other types of malignant tumors, including lung, breast, and oropharyngeal carcinomas, where tumor volume is widely used for predicting prognosis,[@b4-cmar-10-3169] tumor volume is not considered in the TNM-staging system developed by AJCC for NPC. This is inconsistent with the observations by our group and others that primary tumor volume (TV) has a significant value in the prognosis of NPC.[@b5-cmar-10-3169]--[@b9-cmar-10-3169] This had also been confirmed in our previous study.[@b10-cmar-10-3169] Nodal volume (NV) is a critical aspect of tumor burden and primary tumors, and thus, it may also affect patient prognosis of NPC. However, most of the previous studies were confined to the prognostic value of TV in NPC. Very few studies have examined the prognosis value of NV. In this study, we evaluated the prognostic value of tumor burden, including TV and NV. Our goal was to determine whether these two aspects of tumor burden should be considered when evaluating prognosis and establishing a treatment plan for NPC.

Methods
=======

Patients and staging evaluation
-------------------------------

Between May 2002 and September 2009, a total of 992 NPC patients underwent IMRT at our center. Disease staging was performed for all of the patients according to AJCC seventh edition guidelines. All of the patients provided written informed consent for their clinical data to be used for clinical research. A retrospective analysis of these patients' data was approved by the Ethics Committee of Fujian Provincial Cancer Hospital (KT2016-012-01), with patient information anonymized and de-identified prior to analysis. Patient characteristics are summarized in [Table 1](#t1-cmar-10-3169){ref-type="table"}. All of the patients involved have given their written informed consent for this publication.

Study design
------------

Receiver operating characteristic (ROC) curves were generated to assess different cutoff points for TV and NV. An ROC curve is a plot of sensitivity vs specificity for a range of cutoff points, and it facilitates selection of a cutoff point that optimizes sensitivity and specificity for a continuous predictor. According to AJCC T-staging, we then further divided the patients into four groups according to TV, NV, T-stage, and N-stage. The advanced stages were characterized by a larger tumor volume compared with the less advanced stages. Consequently, advanced T-stage was established as a positive parameter in our determinations of rational cutoff points. For example, T2 patients were used as a positive actual state, while T1 patients were used as the negative state, in generating ROC curves. A rational cutoff point was then used as the standard for distinguishing TV1 and TV2.[@b10-cmar-10-3169] A rational cutoff point should maximize the true positive rate and minimize the false positive rate.

The cutoff volumes determined for TV and NV were 12.5, 25.0, and 50.0 mL, and 0, 12.5, and 25 mL, respectively. Based on the four subgroups that were established as TV1--TV4, and the four subgroups that were established as NV0--NV3, all of the NPC patients (n=992) were divided into 16 subgroups. The 16 subgroups were then recombined to form four groups (G1--G4) according to similarities in 5-year overall survival (OS) curves, thereby representing the different levels of tumor burden. The prognostic value of tumor burden, including TV and NV, were subsequently assessed.

Measurements of TV and NV
-------------------------

Pretreatment, contrast-enhanced computed tomography scans were performed from the top of the head to 2 cm below the sternoclavicular joint to assess tumor volume. Briefly, contiguous axial scanning at a slice thickness of 3 mm was imported into a three-dimensional (3D) treatment-planning system, and a radiation oncologist manually outlined the primary lesion in each image by using pretreatment magnetic resonance images as a reference. As a result, the area of the primary tumor and metastatic lymph nodes were independently delineated prior to treatment. Gross tumor volume-primary tumor (GTV-T) included all gross diseases as determined by imaging, clinical, and endoscopic findings. Gross tumor volume-node (GTV-N) was delineated as follows:[@b11-cmar-10-3169],[@b12-cmar-10-3169] 1) lymph node with a minimal axial diameter ≥1 cm, 2) three or more enlarged lymph nodes with a minimal axial diameter of 8 mm, or 3) a lymph node with an irregular enhancement or an enhanced rim. Subsequently, tumor volume, including GTV-T and GTV-N, were automatically calculated by reconstructing a 3D image.

Treatment methods
-----------------

All of the patients in this study were treated with IMRT. In addition, most of the patients received neoadjuvant, concurrent, or adjuvant chemotherapy which consisted of platinum-based drugs. Target volumes were delineated according to an institutional treatment protocol previously defined by our center.[@b10-cmar-10-3169],[@b13-cmar-10-3169] Briefly, a total dose of 66.00--69.96 Gy at 2.0--2.25 Gy/fraction was applied for GTV-T and GTV-N, while 60--66 Gy for high-risk clinical target volume (CTV-1) and 54--60 Gy for low-risk clinical target volume (CTV-2) and lymphatic drainage regions (CTV-N) were also prescribed.

Follow-up
---------

The first evaluation of curative effect was conducted within the first 3 months after completing IMRT. Patients were subsequently evaluated every 3 months within the first 3 years after IMRT, then every 6 months up to the first 5 years, and once a year thereafter. The 5-year local regional relapse-free survival (LRRFS) rate, the 5-year distant failure-free rate (DFFR), the 5-year disease-free survival (DFS) rate, and the 5-year OS rate were calculated from the date of diagnosis to the first defining event and were used to estimate prognosis.

Statistical methods
-------------------

Statistical analyses were performed with SPSS statistical software. The Kaplan--Meier method was used for analyses of patient survival. ROC curves were used to assess different cutoff points for TV and NV. The significance of differences between multiple survival curves was calculated according to the log-rank test. The independent significance of different prognostic factors was analyzed by performing a Cox proportional hazards regression analysis. *P*-values \<0.05 were considered to indicate statistical significance.

Results
=======

The median duration of follow-up was 65.0 months (range, 3--110 months). The 5-year LRRFS, DFFR, DFS, and OS rates for the entire cohort were 90.7%, 85.7%, 74.9%, and 83.2%, respectively. The mean TV was 39.5±30.8 mL (range 1.25--235.6 mL) and the mean NV was 16.5±17.6 mL (range 0--180.8 mL).

Volumes of 12.5, 25.0, and 50.0 mL were determined to be cutoff points for TV. The corresponding sensitivity and 1--specificity values for these cutoff points were 0.656 and 0.248 (area under the ROC curve \[AUC\] =0.71, *P*\<0.001), 0.739 and 0.352 (AUC =0.74, *P*\<0.001), and 0.703 and 0.339 (AUC =0.79, *P*\<0.001), respectively in each case. Volumes of 0, 12.5, and 25 mL were determined to be the cutoff points for NV. The corresponding sensitivity and 1--specificity values for these cutoff points were 0.782 and 0.437 (AUC =0.70, *P*\<0.001) and 0.780 and 0.480 (AUC =0.72, *P*\<0.001). According to these cutoff values, the NPC patients were divided into four subgroups according to TV and NV. The former included TV1 ≤12.5 mL, 12.5 mL \< TV2 ≤ 25 mL, 25 mL\< TV3 ≤ 50 mL, and TV4 \> 50 mL. The latter included NV0 =0 mL, 0 mL \<NV1 ≤12.5 mL, 12.5 mL \< NV2 ≤ 25 mL, and NV3 \>25 mL.

The 5-year OS rates for TV1--TV4 were 92.2%, 89.8%, 84.8%, and 69.5%, respectively (*P*\<0.001). For NV0--NV3, the 5-year OS rates were 90.3%, 85.3%, 83.4%, and 75.2%, respectively (*P*=0.004). Thus, an increase in TV or NV resulted in a marked downward trend in 5-year OS rate. Cumulative survival curves for TV1, TV2, and TV3 were relatively similar and were clearly separated from TV4 ([Figure 1](#f1-cmar-10-3169){ref-type="fig"}). Similarly, NV3 was clearly separated from the other subgroups ([Figure 2](#f2-cmar-10-3169){ref-type="fig"}). In comparison with the other groups, the 5-year OS rates for TV4 and NV3 were significantly lower.

Based on the four subgroups that were established as TV1--TV4, and the four subgroups that were established as NV0--NV3, all of the patients were divided into 16 subgroups. In [Figure 3](#f3-cmar-10-3169){ref-type="fig"}, the 5-year OS rates are shown for each of these 16 subgroups. We then further subdivided the 16 subgroups into four groups according to similarities in 5-year OS rates. This produced G1 (TV1NV0, TV1NV1), G2 (TV1NV2, TV2NV0, TV2NV1, TV2NV2, TV3NV0, TV3NV1, and TV3NV2), G3 (TV1NV3, TV2NV3, TV3NV3, and TV4NV0), and G4 (TV4NV1, TV4NV2, and TV4NV3) subgroups, with the difference in 5-year OS among the subgroups being nearly \<5%.

The 5-year LRRFS, DFFR, DFS, and OS rates for G1--G4 are presented in [Table 2](#t2-cmar-10-3169){ref-type="table"}, and all four rates exhibited a downward trend. The 5-year DFFR, DFS, and OS rates for G3 and G4 were also significantly lower than those for G1 and G2. Moreover, cumulative survival curves for G1--G4 exhibited a significant difference in 5-year OS between the four groups (*P*\<0.001; [Figure 4](#f4-cmar-10-3169){ref-type="fig"}). The cumulative survival curves of TNM stage (sevevth edition, 2010) were also made for a simple comparison and analysis with G1--4 ([Figure 5](#f5-cmar-10-3169){ref-type="fig"}).

The Cox proportional hazards regression model was constructed to calculate the relative risks (RRs) and CIs for different prognostic factors. A multivariate analysis revealed that TV \>50 mL, T3--T4 stage, and N2--N3 stage were adverse prognostic factors for OS.

Discussion
==========

The most widely used primary treatment for NPC is IMRT, and this landmark radiation treatment has greatly improved the quality of life and survival rate of NPC patients by optimizing the dose distribution of radiotherapy. Currently, the AJCC TNM-staging system is the only major indicator available for assessing the prognosis of malignant tumors. However, in several recent studies, a TNM-staging system based on anatomic location was found to be limited in its ability to predict prognosis for NPC patients treated with IMRT.[@b14-cmar-10-3169]--[@b16-cmar-10-3169] In contrast, the prognostic value of TV for NPC patients undergoing IMRT treatment has been confirmed in many studies.

In this study, univariate and multivariate analyses confirmed that TV is a significant prognostic factor for survival rate in NPC, with TV \>50 mL predicting poor treatment outcome. T stage and N stage were also identified as adverse prognostic factors for 5-year OS rate. In the univariate analyses, NV \>25 mL was also shown to predict poor prognosis, yet it did not maintain statistical significance in our multivariate analysis. For the G1--G4 groups, their 5-year LRRFS, DFFR, DFS, and OS rates exhibited a distinct downward trend. Moreover, the cumulative survival curves for G1--G4 were distinct during follow-up. These results indicate that this new prognostic indicator has a significant prognostic value in IMRT therapy for NPC. Furthermore, the prognostic value for tumor burden was found to be comparable to that of clinical staging by the AJCC TNM-staging system.

In previous studies, significance of TV on the prognosis of NPC was confirmed, and various cutoff values for TV were proposed.[@b6-cmar-10-3169],[@b7-cmar-10-3169],[@b10-cmar-10-3169],[@b17-cmar-10-3169] For example, Wu et al[@b7-cmar-10-3169] divided 321 patients into the following three subgroups according to an ROC curve analysis: V1 (\<19 mL, n=94), V2 (19--49 mL, n=154), and V3 (GTV, *P*≥49 mL, n=73). The 5-year distance metastasis free survival (DMFS) rates for these groups were 93.5%, 77.5%, and 66.6%, respectively, and the 5-year OS rates were 96.7%, 84.5%, and 64.6%, respectively. In the multivariate analysis performed in the present study, TV was identified as an independent prognostic factor (*P*\<0.001). In our previous study of 112 NPC patients who underwent IMRT,[@b10-cmar-10-3169] the 5-year OS rate for V1 (\<15.65 mL), V2 (15.65--24.25 mL), V3 (24.25--50.55 mL), and V4 (\>50.55 mL) were 88.5%, 83.3%, 82.4%, and 54.5%, respectively. In addition, the cumulative survival curves for V1--V4 showed a distinct curve for TV \>50 mL. In a study conducted by Feng et al,[@b17-cmar-10-3169] the 5-year OS rates for TV1 (≤20 mL), TV2 (20--30 mL), TV3 (30--40 mL), and TV4 (\>40 mL) were 83.7%, 77.8%, 76.4%, and 61.3%, respectively (*P*=0.002). TV \>40 mL was identified as an independent prognostic factor for the 5-year local and regional control rate in a multivariate analysis (RR: 2.454, *P*=0.002). These results, in combination with those of previous studies, strongly support the prognostic value of TV in NPC. In our univariate analyses in the present study, TV \>50 mL and NV \>25 mL predicted a poor 5-year OS rate. However, in our multivariate analysis, TV \>50 mL still represented an adverse prognostic factor for 5-year OS rate, while NV \>25 mL did not exhibit statistical significance. Similar studies[@b17-cmar-10-3169]--[@b19-cmar-10-3169] have also revealed a correlation between NV and prognosis, although these studies have been relatively infrequent. In the present study, NV predicted poor 5-year OS. It will be important for these results to be confirmed in additional high-quality studies.

Previously, use of TV and NV to predict prognosis has not been extensively examined. In the present study, tumor burden was measured based on both TV and NV, and the relationship between tumor volume burden and prognostic evaluation in NPC patients treated with IMRT was examined. For this, we initially divided 992 NPC patients into 16 subgroups according to four levels of TV (TV1--TV4) and four levels of NV (NV0--NV3). Next, similarities in the 5-year OS curves for these 16 subgroups led to a redistribution of these 16 subgroups into four groups with distinct 5-year OS curves (G1--G4). When the 5-year LRRFS, DFFR, DFS, and OS rates were examined for G1--G4 ([Table 2](#t2-cmar-10-3169){ref-type="table"}), all except LRRFS were significantly worse for G3 and G4 compared with G1 and G2. The differences in the 5-year LRRFS rates for G1--G4 did exhibit a downward trend, although no significant differences were observed. Some scholars have reported that IMRT improves tumor target conformity and clinical efficacy, and this leads to better local control.[@b20-cmar-10-3169]--[@b22-cmar-10-3169] Based on the AJCC staging system, cumulative survival curves were generated according to TNM staging of the 992 NPC patients examined in the present study. These survival curves were clearly distinct, thereby indicating that the AJCC TNM-staging system is appropriate for clinical staging. The cumulative survival curves of groups G1--G4 were also distinct. When our cohort of NPC patients was assigned a clinical stage according to the AJCC TNM-staging system, the proportions for stages I--IV were 5.2%, 23.0%, 44.7%, and 27.1%, respectively. In comparison, the proportions for G1--G4 were 9.7%, 50.0%, 16.0%, and 24.3%, respectively. Currently, the widespread application of IMRT and concurrent chemotherapy has substantially improved the treatment for NPC. However, we would further advocate that NPC patients at an early stage should account for a larger proportion of the patients who undergo treatment. And the proportion of the patients at an advanced stage which has poor prognosis should decline. From this point of view, the proportionality of four groups was more reasonable.

Conclusion
==========

The present results demonstrate that the 5-year OS rate and 5-year DFFR for TV \>50 mL and NV \>25 mL were significantly worse in the univariate analyses performed. Meanwhile, our multivariate analysis showed that TV is a significant prognostic factor in NPC patients receiving IMRT. Our analysis of cumulative survival curves further demonstrated that the establishment of subgroups according to TV and NV, as shown with G1--G4, was found to be comparable to clinical staging in the AJCC TNM-staging system. However, the proportionality of patient distribution of G1--G4 according to clinical stage of the AJCC TNM-staging system was more reasonable. Therefore, in addition to use of the current TNM-staging system, we suggest that tumor burden, including TV and NV, should be considered as prognostic factors when evaluating diagnosis and treatment plans for NPC.
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###### 

Patients' characteristics

  Characteristics                 No. of patients (%)
  ----------------- ------------- -------------------------------------------
  **Age (years)**   Median        45
                    Range         10--86
                    ≥50           356 (35.9%)
                    \<50          639 (64.4%)
  **Gender**        Male          770 (77.6%)
                    Female        222 (22.4%)
  **TNM stage**     T1/T2/T3/T4   125/230/428/209 (12.6%/23.2%/43.1%/21.1%)
                    N0/N1/N2/N3   324/440/150/78 (32.7%/44.3%/15.1%/7.9%)
                    I/II/III/IV   52/228/443/269 (5.2%/23.0%/44.7%/27.1%)

###### 

Treatment outcomes of the different tumor burden

  Prognostic factors   Five-year LRRF   Five-year DFFR   Five-year DFS   Five-year OS
  -------------------- ---------------- ---------------- --------------- --------------
  G1                   96.9%            94.8%            91.7%           95.8%
  G2                   91.9%            91.1%            81.7%           88.9%
  G3                   88.1%            76.1%            65.4%           79.2%
  G4                   87.6%            77.2%            60.6%           68.9%
  *P*                  0.012            \<0.001          \<0.001         \<0.001

**Abbreviations:** DFFR, distant failure-free rate; DFS, disease-free survival; LRRF, local regional relapse free; OS, overall survival.
